Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Brand names appearing in italics throughout this report are trademarks of <strong>Aventis</strong> and/or its affiliates, with the exception of:<br />
- trademarks used or that may be used under license by <strong>Aventis</strong> and / or its affiliates, such as Actonel, a trademark of the Group<br />
Procter & Gamble Pharmaceuticals, Alvesco, a trademark of the Group ALTANA Pharma AG, Campto, a trademark of the Group<br />
Kabushiki Kaisha Yakult Honsha, Copaxone, a trademark of the Group Teva Pharmaceutical Industries, DiaPep277, a trademark<br />
of Peptor Ltd, Exubera, a trademark of the Group Pfizer Products Inc., Genasense, a trademark of Genta Inc. in the U.S., Tavanic,<br />
a trademark of the Group Daiichi Pharmaceutical Co. Ltd. and Mutagrip, a trademark of Institut Pasteur.<br />
- Claritin, a trademark of Schering Corporation<br />
Information Regarding Forward-Looking Statements<br />
Statements in this annual report other than historical information are forward-looking statements subject to risks and uncertainties.<br />
The forward-looking statements in this document speak only of management’s views as at March 1, 2004. Factors that could cause<br />
actual results to differ materially from those expressed or implied include, but are not limited to, impediments to the realization of<br />
integration cost savings as a result of labor or political issues or the difficulties of integrating large and complex businesses while<br />
continuing day-to-day operations, continued evolutions in the business and business environment, actions that may be taken by<br />
competitors or by regulatory authorities, unexpected negative results from research and development of current product candidates,<br />
the effectiveness of patent protection, the result of litigation and other risks and uncertainties that are difficult to predict. There can<br />
be no assurance that we will achieve the results set forth above. Additional information regarding risks and uncertainties is set forth<br />
in the current <strong>Annual</strong> <strong>Report</strong> on Form 20-F of <strong>Aventis</strong> on file with the U.S. Securities and Exchange Commission.<br />
This report has been provided for information purposes only. <strong>Aventis</strong> prepares a legally binding annual report in the French language<br />
known as the “Document de Référence” prior to its <strong>Annual</strong> General Meeting of Shareholders as well as an annual report in the<br />
English language on Form 20-F pursuant to the U.S. Securities Exchange Act of 1934.<br />
All reports can be ordered by phone: 00 800 40 53 43 40 (toll-free) or +49 6192 9 77 08 28<br />
or by e-mail: <strong>Aventis</strong>@mt-w.de<br />
They can also be downloaded from our Web site at www.aventis.com<br />
<strong>Aventis</strong>, a stock corporation with a Supervisory Board and Management Board, and a share capital of e 3 064 758 522.74 – 542 064 308<br />
RCS Strasbourg